Download PDF

1. Company Snapshot

1.a. Company Description

Semler Scientific, Inc.provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers in the United States.The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition.


Its products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, and family practitioners, as well as healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups.The company offers its products through salespersons and distributors.Semler Scientific, Inc.


was incorporated in 2007 and is headquartered in Santa Clara, California.

Show Full description

1.b. Last Insights on SMLR

Negative drivers behind Semler Scientific's recent stock performance include the investigation by Kaskela Law LLC into potential securities law violations and breaches of fiduciary duties by the company's officers and directors. Additionally, the company's recent convertible senior notes offerings, totaling $85 million, may have increased debt and diluted shareholder value. Furthermore, the volatility of its Bitcoin holdings, valued at $147 million, poses a risk to the company's stock price, as regulatory uncertainties and price fluctuations could negatively impact its core business fundamentals.

1.c. Company Highlights

2. Semler Scientific's Bitcoin Strategy Drives Strong Q2 2025 Results

Semler Scientific reported a significant boost in its second-quarter 2025 financial results, primarily driven by its Bitcoin treasury strategy, which generated a 31.3% Bitcoin yield year-to-date, resulting in an $84 million Bitcoin dollar gain. The company's actual EPS came out at $5.04, far exceeding estimates of -$0.1. The substantial gain in Bitcoin value has positively impacted the company's financial performance. Revenue growth estimates for next year are anticipated at -1.9%, indicating a potential decline. The company's health care business is also expanding through its new subsidiary, CardioVanta.

Publication Date: Aug -31

📋 Highlights
  • Bitcoin Yield & Gains:: Achieved 31.3% Bitcoin yield YTD in Q2 2025, generating $84M Bitcoin dollar gain.
  • Bitcoin Holdings Value:: Held 5,021 Bitcoin ($586.2M) as of July 31, 2025, with $110M unrealized gain vs. $476M cost basis.
  • Healthcare Expansion:: Launched CardioVanta to target multi-billion-dollar market for heart failure/arrhythmia detection.
  • Bitcoin Acquisition Target:: Aims for 105,000 Bitcoin by 2027, using intelligent leverage and exploring preferred equity financing.
  • Strategic Leverage Framework:: Adopts "slow money" approach (1x mNAV) with fixed-income liabilities to amplify Bitcoin returns long-term.

Bitcoin Holdings and Strategy

As of July 31, 2025, Semler Scientific held 5,021 Bitcoin, valued at $586.2 million, with a cost basis of $476 million, resulting in an unrealized gain of $110 million. The company is committed to reaching its target of 105,000 Bitcoin by year-end 2027 and is actively exploring various financing options to support its Bitcoin acquisition goals. Semler's management stated, "Our Bitcoin acquisition pace might vary. While we haven't announced recent acquisitions, it doesn't mean we aren't actively accumulating Bitcoin."

Valuation and Leverage

Semler Scientific's current valuation metrics indicate a 'P/E Ratio' of 9.38, a 'P/B Ratio' of 0.91, and an 'EV/EBITDA' of -22.79. The company's use of intelligent leverage is expected to enhance its Bitcoin exposure, potentially amplifying returns if Bitcoin appreciates significantly. The "slow money game" strategy employed by Semler involves leveraging the balance sheet with fixed-income liabilities, which can outperform Bitcoin itself if the appreciation outpaces interest costs.

Growth Prospects and Market Perception

The company's focus on a disciplined, accretive, and stockholder-aligned strategy is expected to drive long-term growth prospects. Semler Scientific remains confident that its stock is undervalued. The attractiveness of intelligently leveraged positions may lead to premiums, ultimately amplifying future Bitcoin returns. The market's enthusiasm for Bitcoin may be a key driver behind these premiums, potentially benefiting Semler Scientific's valuation.

3. NewsRoom

Card image cap

Semler Scientific® to Release Third Quarter 2025 Financial Results

Oct -28

Source: prnewswire.com

Card image cap

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2025 in Semler Scientific, Inc. Lawsuit – SMLR

Oct -28

Source: globenewswire.com

Card image cap

Semler Scientific Deadline: SMLR Investors Have Opportunity to Lead Semler Scientific, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm

Oct -28

Source: prnewswire.com

Card image cap

SMLR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Semler Scientific, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Oct -28

Source: globenewswire.com

Card image cap

SMLR Deadline Today: Rosen Law Firm Encourages Semler Scientific, Inc. Investors to Secure Counsel Before Important October 28 Deadline in Securities Class Action First Filed by the Firm – SMLR

Oct -28

Source: businesswire.com

Card image cap

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Semler Scientific, Inc. of Class Action Lawsuit and Upcoming Deadlines - SMLR

Oct -28

Source: prnewswire.com

Card image cap

SMLR FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Investors of the Semler Scientific Upcoming Lead Plaintiff Deadline on Tuesday, October 28, 2025

Oct -28

Source: prnewswire.com

Card image cap

Semler Scientific, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 28, 2025 to Discuss Your Rights - SMLR

Oct -28

Source: prnewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.47%)

6. Segments

Technology Solutions

Expected Growth: 10.47%

Semler Scientific's Technology Solutions segment growth of 10.47% is driven by increasing demand for its QuantaFlo system, a non-invasive test for peripheral artery disease. Expanding customer base, strategic partnerships, and growing adoption in the healthcare industry also contribute to this growth.

7. Detailed Products

QuantaFlo

A non-invasive, easy-to-use device that measures arterial blood flow in the legs and feet, helping healthcare professionals diagnose and manage peripheral artery disease (PAD).

MAT

A non-invasive, pain-free test that measures arterial stiffness, providing valuable insights into cardiovascular health and risk of cardiovascular disease.

WellChec

A comprehensive, cloud-based platform that enables healthcare providers to manage patient data, track outcomes, and make data-driven decisions to improve patient care.

8. Semler Scientific, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Semler Scientific, Inc. has a low threat of substitutes due to its unique technology and patented products, making it difficult for competitors to replicate.

Bargaining Power Of Customers

Semler Scientific, Inc. has a medium bargaining power of customers due to the presence of a few large customers, but the company's products are still essential for their operations.

Bargaining Power Of Suppliers

Semler Scientific, Inc. has a low bargaining power of suppliers due to its ability to negotiate prices and terms with its suppliers.

Threat Of New Entrants

Semler Scientific, Inc. has a high threat of new entrants due to the growing demand for its products and the potential for new companies to enter the market.

Intensity Of Rivalry

Semler Scientific, Inc. has a medium intensity of rivalry due to the presence of a few competitors, but the company's unique products and technology give it a competitive advantage.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 0.22%
Debt Cost 3.95%
Equity Weight 99.78%
Equity Cost 8.53%
WACC 8.52%
Leverage 0.22%

11. Quality Control: Semler Scientific, Inc. passed 8 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
LENSAR

A-Score: 5.7/10

Value: 8.8

Growth: 5.0

Quality: 5.8

Yield: 0.0

Momentum: 10.0

Volatility: 4.7

1-Year Total Return ->

View Full Report
Stock-Card
Semler Scientific

A-Score: 4.9/10

Value: 7.5

Growth: 7.3

Quality: 7.2

Yield: 0.0

Momentum: 6.5

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
NeuroPace

A-Score: 4.3/10

Value: 6.4

Growth: 4.8

Quality: 3.9

Yield: 0.0

Momentum: 8.5

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Quipt Home Medical

A-Score: 3.8/10

Value: 8.7

Growth: 6.7

Quality: 3.8

Yield: 0.0

Momentum: 2.5

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Talis Biomedical

A-Score: 3.7/10

Value: 8.2

Growth: 4.6

Quality: 4.4

Yield: 0.0

Momentum: 3.5

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Myomo

A-Score: 2.9/10

Value: 8.0

Growth: 4.7

Quality: 4.3

Yield: 0.0

Momentum: 0.0

Volatility: 0.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

18.67$

Current Price

18.67$

Potential

-0.00%

Expected Cash-Flows